Tempest Therapeutics, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
▼ Likely negative
significance 68/100
What the filing says
On May 22-23, 2026, Stephen Brady, Christine Pellizzari, Michael Raab, and Ronit Simantov resigned from Tempest's Board effective immediately. Each executed mutual release agreements with no material severance disclosed. Separately, Nicholas Maestas (employee) separated June 5, 2026, receiving $213,667 severance (4.5 months base + 75% pro-rated bonus) plus 6 months COBRA. Justin Trojanowski was promoted to VP Finance, Principal Financial Officer, and Corporate Secretary (base $279,200, 25% target bonus) effective June 4, 2026. No dollar amounts stated for board compensation or reasons for departures.
Why this rating
Simultaneous loss of four directors plus key employee separation signals governance instability at tiny $30M company. Material for size, though no disclosed disputes or quantified board impact.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.